{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:03:44Z","timestamp":1790129024172,"version":"4.0.1"},"reference-count":58,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Propranolol, a nonselective B1\/B2 adrenoceptor antagonist, promotes the regression of infantile hemangiomas likely through suppression of vascular endothelial growth factor (VEGF), which prompted its use for the prevention of retinopathy of prematurity. We tested the hypothesis that topical ocular propranolol is safe and effective for reducing the severity of oxygen-induced retinopathy (OIR) in the neonatal rat intermittent hypoxia (IH) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      At birth (P0), rat pups were randomly assigned to room air or neonatal intermittent hypoxia (IH) consisting of 50% O\n                      <jats:sub>2<\/jats:sub>\n                      with brief episodes of hypoxia (12% O\n                      <jats:sub>2<\/jats:sub>\n                      ) from P0 to P14, during which they received a single daily dose of oral propranolol (1\u2009mg\/kg\/day in 50\u2009\u03bcL in sterile normal saline) or topical ocular propranolol (0.2% in 10\u2009\u03bcL in normal saline) from P5 to P14. Placebo-controlled littermates received 50\u2009\u03bcL oral or 10\u2009\u03bcL topical ocular sterile normal saline. Retinal vascular and astrocyte integrity; retinal histopathology and morphometry; and angiogenesis biomarkers were determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Topical ocular propranolol improved retinal vascular damage and preserved the astrocytic template, but did not completely prevent OIR. The beneficial effects of propranolol were associated with reduced ocular VEGF and increased endogenous soluble inhibitor, sVEGFR-1, when administered topically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Propranolol failed to completely prevent severe OIR, however, it prevented astrocyte degeneration resulting from neonatal IH-induced damage. We conclude that the mechanisms of propranolol's beneficial effects in neonatal IH may involve in part, astrocyte preservation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0092","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T17:34:21Z","timestamp":1612373661000},"page":"112-130","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ocular Versus Oral Propranolol for Prevention and\/or Treatment of Oxygen-Induced Retinopathy in a Rat Model"],"prefix":"10.1177","volume":"37","author":[{"given":"Areej","family":"Qadri","sequence":"first","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Cai","sequence":"additional","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Deslouches","sequence":"additional","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob V.","family":"Aranda","sequence":"additional","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."},{"name":"Department of Ophthalmology, Downstate Medical Center, State University of New York, Brooklyn, New York, USA."},{"name":"State University of New York Eye Institute, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay D.","family":"Beharry","sequence":"additional","affiliation":[{"name":"Division of Neonatal\/Perinatal Medicine, Department of Pediatrics, State University of New York, Brooklyn, New York, USA."},{"name":"Department of Ophthalmology, Downstate Medical Center, State University of New York, Brooklyn, New York, USA."},{"name":"State University of New York Eye Institute, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.009"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2004.03.030"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.01.046"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2012.132"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-4584-1_47"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000329922"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92475-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2008.05.001"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9066-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181644ad2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20181101-11"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.08.2010.3224"},{"key":"e_1_3_4_16_2","first-page":"4353129","article-title":"Ocular adverse effects of intravitreal bevacizumab are potentiated by intermittent hypoxia in a rat model of oxygen-induced retinopathy","volume":"2017","author":"Tan J.","year":"2017","unstructured":"Tan J., , Cai C.L., , Shrier E.M., et al. Ocular adverse effects of intravitreal bevacizumab are potentiated by intermittent hypoxia in a rat model of oxygen-induced retinopathy. J. Ophthalmol. 2017:4353129, 2017.","journal-title":"J. Ophthalmol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051337"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2016.105"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-311548"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2016.230"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2016.1158272"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2015-0357"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021749"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.03.013"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5536"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/jiaps.JIAPS_22_19"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-013-1966-y"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404710"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0503-x"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.07.049"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00180"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-3806(97)00004-7"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.041860jz"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000115306"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13040"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/apa.14049"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.31"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490465874"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvs136"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.5.1016"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087587"},{"key":"e_1_3_4_42_2","first-page":"e488","article-title":"Impact of chronic neonatal intermittent hypoxia on severity of retinal damage in a rat model of oxygen-induced retinopathy","volume":"4","author":"Beharry K.D.","year":"2018","unstructured":"Beharry K.D., , Cai C.L., , Ahmad T., , Guzel S., , Valencia G.B., , and Aranda J.V. Impact of chronic neonatal intermittent hypoxia on severity of retinal damage in a rat model of oxygen-induced retinopathy. J. Nat. Sci. 4:e488, 2018.","journal-title":"J. Nat. Sci"},{"key":"e_1_3_4_43_2","first-page":"1111","article-title":"Graded contribution of retinal maturation to the development of oxygen-induced retinopathy in rats","volume":"42","author":"Dembinska O.","year":"2001","unstructured":"Dembinska O. Graded contribution of retinal maturation to the development of oxygen-induced retinopathy in rats. Invest. Ophthalmol. Vis. Sci. 42:1111\u20131118, 2001.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13630"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2013.02.004"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00498752"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2012.755169"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(88)90283-9"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.05.001"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.586"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.161570"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2011.11.006"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1169"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.03.027"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20997"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.187"},{"key":"e_1_3_4_58_2","first-page":"569","article-title":"Spectral-domain optical coherence tomographic assessment of severity of cystoid macular edema in retinopathy of prematurity Arch","volume":"130","author":"Maldonado R.S.","year":"2012","unstructured":"Maldonado R.S., , O'Connell R., , Ascher S.B., et al. Spectral-domain optical coherence tomographic assessment of severity of cystoid macular edema in retinopathy of prematurity Arch. Ophthalmol. 130:569-578, 2012.","journal-title":"Ophthalmol"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00076"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:15Z","timestamp":1777646655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["10.1089\/jop.2020.0092"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0092","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}